JPWO2022049372A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022049372A5 JPWO2022049372A5 JP2023513654A JP2023513654A JPWO2022049372A5 JP WO2022049372 A5 JPWO2022049372 A5 JP WO2022049372A5 JP 2023513654 A JP2023513654 A JP 2023513654A JP 2023513654 A JP2023513654 A JP 2023513654A JP WO2022049372 A5 JPWO2022049372 A5 JP WO2022049372A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- compound
- isobutylthiophen
- imidazol
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 33
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims 3
- -1 4-fluorobenzyl(3-(4-((2-ethyl-1H-imidazol-1-yl)methyl)-3-fluorophenyl)-5-isobutylthiophen-2-yl)sulfonylcarbamate Chemical compound 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 125000005024 alkenyl aryl group Chemical group 0.000 claims 2
- 125000005217 alkenylheteroaryl group Chemical group 0.000 claims 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- WIWOUVWLGNHSFS-UHFFFAOYSA-N ethyl N-[3-[3-fluoro-4-[(2-methylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CCOC(NS(C(SC(CC(C)C)=C1)=C1C1=CC(F)=C(CN2C(C)=NC=C2)C=C1)(=O)=O)=O WIWOUVWLGNHSFS-UHFFFAOYSA-N 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- KVEFLMVVBXUJSC-UHFFFAOYSA-N methyl N-[3-[3-fluoro-4-[(2-methylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C=C2)=C1S(NC(OC)=O)(=O)=O KVEFLMVVBXUJSC-UHFFFAOYSA-N 0.000 claims 2
- PJTYODLRDCSDPE-UHFFFAOYSA-N methyl N-[3-[4-[(2-ethylimidazol-1-yl)methyl]-3-fluorophenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CCC1=NC=CN1CC(C=CC(C(C=C(CC(C)C)S1)=C1S(NC(OC)=O)(=O)=O)=C1)=C1F PJTYODLRDCSDPE-UHFFFAOYSA-N 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical class C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- PZCSLWCLIHVJGB-UHFFFAOYSA-N 2-[[3-[3-fluoro-4-[(2-methylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamoyloxy]ethyl 2,2-dimethylpropanoate Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C=C2)=C1S(NC(OCCOC(C(C)(C)C)=O)=O)(=O)=O PZCSLWCLIHVJGB-UHFFFAOYSA-N 0.000 claims 1
- XYRUNCVQQVJFRA-UHFFFAOYSA-N 2-hydroxyethyl N-[3-[3,5-difluoro-4-[(2-methylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C(F)=C2)=C1S(NC(OCCO)=O)(=O)=O XYRUNCVQQVJFRA-UHFFFAOYSA-N 0.000 claims 1
- JVZVIYORWWMWTR-UHFFFAOYSA-N 2-hydroxyethyl N-[3-[3-fluoro-4-[(2-methylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C=C2)=C1S(NC(OCCO)=O)(=O)=O JVZVIYORWWMWTR-UHFFFAOYSA-N 0.000 claims 1
- FBPBUHOIKBELDJ-UHFFFAOYSA-N 2-hydroxyethyl N-[3-[3-fluoro-4-[(2-propan-2-ylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)C)=NC=C3)C=C2)=C1S(NC(OCCO)=O)(=O)=O FBPBUHOIKBELDJ-UHFFFAOYSA-N 0.000 claims 1
- BBVABVASFILHMF-UHFFFAOYSA-N 2-hydroxyethyl N-[3-[4-[(2-ethylimidazol-1-yl)methyl]-3-fluorophenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CCC1=NC=CN1CC(C=CC(C(C=C(CC(C)C)S1)=C1S(NC(OCCO)=O)(=O)=O)=C1)=C1F BBVABVASFILHMF-UHFFFAOYSA-N 0.000 claims 1
- JJKGVTVHBWSQLI-UHFFFAOYSA-N 2-hydroxyethyl N-[3-[4-[(2-tert-butylimidazol-1-yl)methyl]-3-fluorophenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)(C)C)=NC=C3)C=C2)=C1S(NC(OCCO)=O)(=O)=O JJKGVTVHBWSQLI-UHFFFAOYSA-N 0.000 claims 1
- MZUCVQIQJXOAMG-UHFFFAOYSA-N 2-methoxyethyl N-[3-[3-fluoro-4-[(2-methylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C=C2)=C1S(NC(OCCOC)=O)(=O)=O MZUCVQIQJXOAMG-UHFFFAOYSA-N 0.000 claims 1
- GZRKGKFZEBUJQD-UHFFFAOYSA-N 2-phenoxyethyl N-[3-[3-fluoro-4-[(2-methylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C=C2)=C1S(NC(OCCOC1=CC=CC=C1)=O)(=O)=O GZRKGKFZEBUJQD-UHFFFAOYSA-N 0.000 claims 1
- BGINLQAMQWIHMI-UHFFFAOYSA-N 3,3,3-trifluoropropyl N-[3-[4-[(2-ethylimidazol-1-yl)methyl]-3-fluorophenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CCC1=NC=CN1CC(C=CC(C(C=C(CC(C)C)S1)=C1S(NC(OCCC(F)(F)F)=O)(=O)=O)=C1)=C1F BGINLQAMQWIHMI-UHFFFAOYSA-N 0.000 claims 1
- QZKLDRYNCFDRKL-UHFFFAOYSA-N C(C)C=1N(C=CN=1)CC1=C(C=C(C=C1)C1=C(SC(=C1)CC(C)C)S(=O)(=O)NC(OCC)=O)F Chemical compound C(C)C=1N(C=CN=1)CC1=C(C=C(C=C1)C1=C(SC(=C1)CC(C)C)S(=O)(=O)NC(OCC)=O)F QZKLDRYNCFDRKL-UHFFFAOYSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- MMVNADREDBSQDY-UHFFFAOYSA-N N-[3-[3-fluoro-4-[(2-methylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonyl-2,2-dimethylpropanamide Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C)=NC=C3)C=C2)=C1S(NC(C(C)(C)C)=O)(=O)=O MMVNADREDBSQDY-UHFFFAOYSA-N 0.000 claims 1
- OFYQTSODHCJVEL-UHFFFAOYSA-N N-[3-[3-fluoro-4-[(2-propan-2-ylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonyl-3-pyridin-2-ylpropanamide Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)C)=NC=C3)C=C2)=C1S(NC(CCC1=NC=CC=C1)=O)(=O)=O OFYQTSODHCJVEL-UHFFFAOYSA-N 0.000 claims 1
- HVYWFEHYUCYTJN-UHFFFAOYSA-N N-[3-[3-fluoro-4-[(2-propan-2-ylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylbenzamide Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)C)=NC=C3)C=C2)=C1S(NC(C1=CC=CC=C1)=O)(=O)=O HVYWFEHYUCYTJN-UHFFFAOYSA-N 0.000 claims 1
- QYBNGVLXAXKUAZ-UHFFFAOYSA-N N-[3-[3-fluoro-4-[(2-propan-2-ylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylpyridine-2-carboxamide Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)C)=NC=C3)C=C2)=C1S(NC(C1=NC=CC=C1)=O)(=O)=O QYBNGVLXAXKUAZ-UHFFFAOYSA-N 0.000 claims 1
- JZPOQZPVOFUXCZ-UHFFFAOYSA-N N-[3-[4-[(2-tert-butylimidazol-1-yl)methyl]-3-fluorophenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylbenzamide Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)(C)C)=NC=C3)C=C2)=C1S(NC(C1=CC=CC=C1)=O)(=O)=O JZPOQZPVOFUXCZ-UHFFFAOYSA-N 0.000 claims 1
- VTCJBXFEYSBSPH-UHFFFAOYSA-N N-[3-[4-[(2-tert-butylimidazol-1-yl)methyl]-3-fluorophenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylpyridine-2-carboxamide Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)(C)C)=NC=C3)C=C2)=C1S(NC(C1=NC=CC=C1)=O)(=O)=O VTCJBXFEYSBSPH-UHFFFAOYSA-N 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- MBMSVXZBRLCJBA-UHFFFAOYSA-N butyl N-[3-[3-fluoro-4-[(2-methylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CCCCOC(NS(C(SC(CC(C)C)=C1)=C1C1=CC(F)=C(CN2C(C)=NC=C2)C=C1)(=O)=O)=O MBMSVXZBRLCJBA-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- CLMCYMLAOPTERN-UHFFFAOYSA-N ethyl N-[3-[3-fluoro-4-[(2-propan-2-ylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CCOC(NS(C(SC(CC(C)C)=C1)=C1C1=CC(F)=C(CN2C(C(C)C)=NC=C2)C=C1)(=O)=O)=O CLMCYMLAOPTERN-UHFFFAOYSA-N 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- ITYAXIMJTQWQNV-UHFFFAOYSA-N methyl N-[3-[3-fluoro-4-[(2-propan-2-ylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)C)=NC=C3)C=C2)=C1S(NC(OC)=O)(=O)=O ITYAXIMJTQWQNV-UHFFFAOYSA-N 0.000 claims 1
- XZEZAVFSEYYIRW-UHFFFAOYSA-N methyl N-[3-[4-[(2-tert-butylimidazol-1-yl)methyl]-3-fluorophenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound CC(C)CC(S1)=CC(C2=CC(F)=C(CN3C(C(C)(C)C)=NC=C3)C=C2)=C1S(NC(OC)=O)(=O)=O XZEZAVFSEYYIRW-UHFFFAOYSA-N 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2013721.2 | 2020-09-01 | ||
| GBGB2013721.2A GB202013721D0 (en) | 2020-09-01 | 2020-09-01 | New compounds |
| PCT/GB2021/052254 WO2022049372A1 (en) | 2020-09-01 | 2021-09-01 | Novel compounds for use in the treatment of diseases associated with angiotensin ii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539614A JP2023539614A (ja) | 2023-09-15 |
| JP2023539614A5 JP2023539614A5 (https=) | 2024-09-05 |
| JPWO2022049372A5 true JPWO2022049372A5 (https=) | 2024-09-05 |
Family
ID=72749608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513654A Pending JP2023539614A (ja) | 2020-09-01 | 2021-09-01 | アンジオテンシンｉｉに関連する疾患の治療に使用するための新規化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230348444A1 (https=) |
| EP (1) | EP4208460A1 (https=) |
| JP (1) | JP2023539614A (https=) |
| KR (1) | KR20230058467A (https=) |
| CN (1) | CN116568682A (https=) |
| AU (1) | AU2021337193A1 (https=) |
| CA (1) | CA3189240A1 (https=) |
| CL (1) | CL2023000580A1 (https=) |
| CO (1) | CO2023002347A2 (https=) |
| GB (1) | GB202013721D0 (https=) |
| IL (1) | IL300582A (https=) |
| MX (1) | MX2023002522A (https=) |
| WO (1) | WO2022049372A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4313953A1 (en) * | 2021-03-23 | 2024-02-07 | Vicore Pharma AB | Selective angiotensin ii receptor ligands |
| GB202104033D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| GB202104038D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| WO2024149712A1 (en) * | 2023-01-09 | 2024-07-18 | Vicore Pharma Ab | Selective angiotensin ii compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
| KR100938817B1 (ko) * | 2001-05-31 | 2010-01-26 | 바이코어 파마 아베 | 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물 |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| WO2004046141A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| AU2006235698B2 (en) * | 2005-04-12 | 2012-03-29 | Vicore Pharma Ab | New tricyclic angiotensin II agonists |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| BR112017012337A2 (pt) | 2014-12-12 | 2018-02-27 | Vicore Pharma Ab | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. |
| WO2016107879A2 (en) | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| CN107405406A (zh) | 2015-03-02 | 2017-11-28 | 维科尔药物公司 | 用于治疗肺纤维化的血管紧张素ii受体激动剂 |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| GB201913603D0 (en) * | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
-
2020
- 2020-09-01 GB GBGB2013721.2A patent/GB202013721D0/en not_active Ceased
-
2021
- 2021-09-01 EP EP21773137.1A patent/EP4208460A1/en active Pending
- 2021-09-01 WO PCT/GB2021/052254 patent/WO2022049372A1/en not_active Ceased
- 2021-09-01 KR KR1020237010733A patent/KR20230058467A/ko not_active Withdrawn
- 2021-09-01 AU AU2021337193A patent/AU2021337193A1/en not_active Abandoned
- 2021-09-01 JP JP2023513654A patent/JP2023539614A/ja active Pending
- 2021-09-01 CA CA3189240A patent/CA3189240A1/en active Pending
- 2021-09-01 US US18/023,164 patent/US20230348444A1/en active Pending
- 2021-09-01 IL IL300582A patent/IL300582A/en unknown
- 2021-09-01 CN CN202180053934.XA patent/CN116568682A/zh active Pending
- 2021-09-01 MX MX2023002522A patent/MX2023002522A/es unknown
-
2023
- 2023-02-28 CL CL2023000580A patent/CL2023000580A1/es unknown
- 2023-02-28 CO CONC2023/0002347A patent/CO2023002347A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007502264A5 (https=) | ||
| JP4773972B2 (ja) | Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸 | |
| JP2009524611A5 (ja) | Ｓ１ｐ１受容体アゴニスト、免疫抑制剤および抗炎症剤としての３，５ージ（アリールまたはヘテロアリール）イソキサゾールおよび１，２，４−オキサジアゾール | |
| JP2017533895A5 (https=) | ||
| JP2002529532A5 (https=) | ||
| JP2005524609A5 (https=) | ||
| JP2008508214A (ja) | 女性の性障害の治療用ピペラジン誘導体 | |
| JP2013506679A (ja) | リゾホスファチジン酸受容体アンタゴニストとしての多環式化合物 | |
| JP2000516593A (ja) | 糖尿病及び肥満症の治療に用いられる選択的β▲下３▼作動物質としての置換スルホンアミド | |
| JP2006506373A5 (https=) | ||
| JP2013526494A5 (https=) | ||
| JP5329656B2 (ja) | イミダゾリジン誘導体 | |
| JP2019522628A5 (https=) | ||
| CN110156698B (zh) | 2-苯基-1，6-二氢嘧啶-5-甲酸衍生物的制备方法和用途 | |
| JP2003505383A5 (https=) | ||
| WO2016030310A1 (en) | Substituted azetidine derivatives as taar ligands | |
| JPWO2021053344A5 (https=) | ||
| JPWO2022049372A5 (https=) | ||
| CA2804473C (en) | 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate (s1p) receptors | |
| JP2009500409A (ja) | 痛みを処置するためのα２アドレナリン作動剤 | |
| JP2014502273A (ja) | スフィンゴシン−１−リン酸（ｓ１ｐ）受容体モジュレーターとしての新規ベンジルアゼチジン誘導体 | |
| JP2004536079A5 (https=) | ||
| CN1181079A (zh) | 作为阿朴脂蛋白－b合成抑制剂的新型三唑酮 | |
| JPWO2021186185A5 (https=) | ||
| JPWO2022200786A5 (https=) |